Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Sold by Welch & Forbes LLC

Welch & Forbes LLC reduced its stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNAFree Report) by 47.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 30,000 shares of the company’s stock after selling 26,750 shares during the period. Welch & Forbes LLC owned 0.05% of Ginkgo Bioworks worth $295,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. PDT Partners LLC bought a new stake in Ginkgo Bioworks in the third quarter worth about $1,199,000. Erste Asset Management GmbH bought a new stake in shares of Ginkgo Bioworks in the 3rd quarter worth approximately $4,075,000. Jacobs Levy Equity Management Inc. bought a new stake in shares of Ginkgo Bioworks in the 3rd quarter worth approximately $2,282,000. BNP Paribas Financial Markets acquired a new stake in Ginkgo Bioworks during the third quarter valued at approximately $1,287,000. Finally, Verition Fund Management LLC bought a new stake in Ginkgo Bioworks during the third quarter worth approximately $792,000. 78.63% of the stock is currently owned by institutional investors.

Ginkgo Bioworks Stock Performance

NYSE DNA opened at $7.56 on Friday. The stock has a market capitalization of $434.71 million, a P/E ratio of -0.58 and a beta of 1.23. The business’s fifty day moving average is $11.32 and its two-hundred day moving average is $9.30. Ginkgo Bioworks Holdings, Inc. has a 1 year low of $5.26 and a 1 year high of $50.40.

Ginkgo Bioworks Profile

(Free Report)

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.

Recommended Stories

Institutional Ownership by Quarter for Ginkgo Bioworks (NYSE:DNA)

Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.